KYMERA THERAPEUTICS I

Kymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology

05 May 2021 06:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present at Upcoming May Investor Conferences

04 May 2021 06:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present New In Vivo Data Demonstrating the Broad Anti-Inflammatory Activity of its IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting

03 May 2021 15:00:40 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Positive Late-Breaking Data from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology 2021 Annual Meeting

03 May 2021 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work Company

19 Apr 2021 06:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021

10 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology (SID) 2021 Annual Meeting

09 Apr 2021 06:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors

16 Mar 2021 15:01:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update

11 Mar 2021 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases

02 Mar 2021 06:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present at Upcoming March Investor Conferences

25 Feb 2021 06:00:03 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present at Upcoming February Investor Conferences

04 Feb 2021 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Strengthens Leadership with Key Appointments and Promotions

03 Feb 2021 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company

12 Jan 2021 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021

05 Jan 2021 15:01:00 By Nasdaq GlobeNewswire